SCHEMBL6490108

SCHEMBL6490108

COC(=O)c1ccccc1COc1ccc(NC(=O)OC(C)(C)C)c(NCc2ccc(-c3ccccc3)cc2Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.41
NR1H3 Q13133 4/20 0.41
RXRA P19793 3/20 0.41
PTPN1 P18031 1/20 0.39
HIF1A Q16665 1/20 0.38
MAOB P27338 1/20 0.37
HDAC1 Q13547 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
ATR Q13535 1/20 0.36
RAB9A P51151 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
BCL2 P10415 2/20 0.35
MAPT P10636 2/20 0.35
MCL1 Q07820 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ACLY P53396 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497144 0.80 LMNA (0.42) HIF1AMAOBKDM4EALDH1A1RAB9A
SCHEMBL6490670 0.77 HDAC1 (0.44) PTPN1HIF1AHDAC1KDM4EALDH1A1
SCHEMBL6490529 0.74 SMN1; SMN2 (0.46) ALDH1A1RAB9AMEN1KMT2AMAPT
SCHEMBL6492750 0.72 KDM4E (0.43) HDAC1KDM4EALDH1A1RAB9AMEN1
SCHEMBL6500991 0.70 ALOX5AP (0.42) ALDH1A1BCL2MAPTMCL1SMN1; SMN2
SCHEMBL7065211 0.69 IDO1 (0.39) HDAC1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6489317 0.69 MTNR1A (0.42) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL27960495 0.69 ALDH1A1 (0.50) MAOBHDAC1KDM4EALDH1A1RAB9A
SCHEMBL6501452 0.68 IDO1 (0.41) HDAC1KDM4EALDH1A1MEN1KMT2A
SCHEMBL25430887 0.68 PTPN1 (0.61) PTPN1HDAC1KDM4EMCL1ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD NR1H2 3132/4885NR1H3 3173/4885RXRA 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.